 |
|
High-Dose Intra-arterial Cisplatin Therapy Followed by Radiation Therapy for Advanced Squamous Cell Carcinoma of the Head and Neck
William R. Wilson, MD;
Robert S. Siegel, MD;
Leonidas A. Harisiadis, MD;
David O. Davis, MD;
Hoang H. Nguyen, MPH;
William O. Bank, MD
Arch Otolaryngol Head Neck Surg. 2001;127:809-812.
Objective To assess the effectiveness of a protocol consisting of 4 cycles of
high-dose intra-arterial cisplatin infusions followed by radiation therapy
for improving chemotherapy response rates, organ preservation, and survival
in patients with advanced-stage untreated and previously treated squamous
cell carcinoma of the head and neck.
Design and Setting A prospective study of sequentially enrolled patients treated in an
academic medical center. The Kaplan-Meier method was used for survival analysis.
Patients Fifty-eight nonpregnant adults, 18 years of age or older, with measurable
untreated or recurrent advanced biopsy-proven squamous cell carcinoma of the
head and neck.
Main Outcome Measures Response rate to targeted intra-arterial cisplatin infusions, organ
preservation, and survival.
Results Fifty-eight patients (44 men and 14 women) were followed up for at least
2 years (median duration of follow-up, 27 months). Twenty-nine (67%) of the
43 previously untreated patients had a complete response to intra-arterial
cisplatin therapy. Of the untreated patients, 28 are alive and disease free
after a median follow-up time of 30 months. Five of the patients with recurrent
disease had a complete response to intra-arterial cisplatin therapy. There
were 4 survivors after a median follow-up time of 17.5 months. Of note, there
were no deaths or serious complications related to the treatment in either
group.
Conclusions High-dose intra-arterial cisplatin therapy provides a high complete
and partial response rate (91%). The combination of high-dose intra-arterial
cisplatin and radiation therapy is effective in improving survival and organ
preservation rates in patients with previously untreated, advanced squamous
cell carcinoma of the head and neck. This treatment protocol is much less
effective for recurrent disease.
From the Divisions of Otolaryngology (Dr Wilson), Hematology and Oncology
(Dr Siegel and Mr Nguyen), Radiation Oncology (Dr Harisiadis), Radiology (Dr
Davis), and Interventional Neuroradiology (Dr Bank), George Washington University
Medical Center, and the Washington Hospital Center, Washington, DC.
RELATED ARTICLE
Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2001;127(7):889-890.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Role of Computed Tomographic Scans in the Management of the N-Positive Neck in Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy
Velazquez et al.
Arch Otolaryngol Head Neck Surg 2004;130:74-77.
ABSTRACT
| FULL TEXT
A Novel Intraarterial Chemotherapy Using Paclitaxel in Albumin Nanoparticles to Treat Advanced Squamous Cell Carcinoma of the Tongue: Preliminary Findings
Damascelli et al.
Am. J. Roentgenol. 2003;181:253-260.
ABSTRACT
| FULL TEXT
|
